The role of early lung ultrasound score measurement in determining prognosis in COVID-19 ICU patients with respiratory failure

The utility of lung ultrasound (LUS) in evaluation of coronavirus disease (COVID-19) with pneumonia has not yet been elucidated. The main objective of study is to determine whether LUS can effectively predict the prognosis in intensive care unit (ICU), including mortality and disease severity. It’s also aimed to determine whether LUS will provide a threshold value to predict mortality in COVID-19 cases. In this prospective observational study, 90 patients admitted to the ICU with COVID-19 pneumonia and respiratory failure were included. A LUS cutoff score of 21 on admission demonstrated sensitivity of 97% and specificity of 68% for predicting mortality. Baseline LUS scores were found to be significantly higher in nonsurvivor group(P < .001) whereas APACHE II, sequential organ failure assessment (SOFA), charlson comorbidity index (CCI), nutrition risk in critically ill (NUTRIC) scores, serum lactate, procalcitonin, ferritin, D-dimer levels and heart rate were also significantly found to be higher in nonsurvivor group(P < .05). Overall mean progression-free-survival (PFS) rate was significantly longer in patients with LUS scores < 21, (mean-survival 23.8 days) compared to those with LUS scores ≥ 21 (mean-survival 12.5 days) (P < .05). Multivariate Cox-regression analysis identified a LUS score ≥ 21 was an independent risk factor for mortality during ICU stay (P = .002). LUS performed at ICU admission can serve as a prognostic indicator for patients with COVID-19 pneumonia. By identifying high-risk groups and monitoring these patients closely using LUS, healthcare providers may enhance resource utilization and potentially improve patient outcomes.